Telomir Pharmaceuticals, Inc. TELO 深 沪
等待开盘 05-19 09:30:00 美东时间
1.19
-0.070
-5.56%
华盛通- 最 高1.2574
- 今 开1.25
- 成交量 9.09万股
- 最 低 1.185
- 昨 收 1.26
- 总市值 8184.22万
- 52周最高 3.10
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 1.05
- 委 比 93.21%
- 总股本 6877.50万
- 历史最高 20.72
- 量 比 1.06
- 振 幅 5.75%
- 历史最低 1.05
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多EXCLUSIVE: Telomir Pharmaceuticals Secures FDA Nod For Its Breast Cancer Therapy To Advance Into Human Study
Telomir wins FDA IND clearance for Telomir-Zn in TNBC, enabling a Phase 1/2 study targeting epigenetic cancer pathways.
04-30 19:46
Telomir Pharmaceuticals Submits Investigational New Drug Application To FDA To Treat Advanced And Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), a biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of cancer and age-related disease, today
03-31 20:23
Telomir Pharmaceuticals Announces New Data Supporting Telomir-Zn's Mechanism In Cancer And Aging, Plans Submission For Investigational New Drug Application In Q1 2026
Cellular findings show Telomir-Zn modulates intracellular metal balance linked to oxidative stress, mitochondrial dysfunction, DNA methylation instability, and genomic integrity-without relying on cytotoxic mechanisms.
02-05 21:09
Telomir Highlights Positive Preclinical Results for Telomir-1 in TNBC
Telomir Pharmaceuticals, Inc. ( ($TELO) ) just unveiled an update. Telomir Phar...
01-05 21:39
Telomir Pharmaceuticals Results From Trial In Zebrafish Tumor Xenograft Animal Models Of Triple-Negative Breast Cancer Shows Reductions In Primary Tumor Growth, Spread Of Cancer Cells
Telomir Pharmaceuticals (NASDAQ:TELO) ("Telomir" or the "Company"), a preclinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic drivers of diseases, today announced
01-05 21:07
Telomir Pharma Announces Results From Comprehensive Series Of IND-Enabling GLP Toxicology And Safety Pharmacology Studies For Telomir-1
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following oral administration.MIAMI, FL / ACCESS Newswire / December 18, 2025 / Telomir Pharmaceuticals,
2025-12-18 20:32
Telomir Pharmaceuticals Announces Telomir-1 Shown To Kill Aggressive Human Leukemia Cells
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells The findings expand Telomir-1's oncology profile into cancers of the blood, adding to previously reported activity in triple-negative
2025-11-21 05:05
Telomir Pharmaceuticals Q3 EPS $(0.03) Beats $(0.07) Estimate
Telomir Pharmaceuticals (NASDAQ:TELO) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 85 percent increase over losses of $(0.20) per share
2025-11-11 07:00
Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data
The latest announcement is out from Telomir Pharmaceuticals, Inc. ( ($TELO) ). ...
2025-10-23 04:40
Telomir Pharmaceuticals executes LOI for worldwide rights to Telomir-1
Telomir Pharmaceuticals (NASDAQ:TELO) said on Tuesday that it has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, securing worldwide rights to its lead investigational therapy, T...
2025-10-21 20:10
